Measuring the knowledge translation and convergence in pharmaceutical innovation by funding-science-technology-innovation linkages analysis. Issue 1 (February 2019)

• Record Type: Journal Article
• Authors: Du, Jian; Li, Peixin; Guo, Qianying; Tang, Xiaoli
• Is Part Of: Journal of informetrics. Volume 13:Issue 1(2019)
• Page Start: 132
• Page End: 148
• Publication Date: 2019-02
• Subjects: Translational research -- Scientometric analysis -- Science policy -- FDA Orange book -- Non-patent literature; Library statistics -- Periodicals; Information science -- Statistical methods -- Periodicals; Bibliometrics -- Periodicals; Bibliothèques -- Statistiques -- Périodiques; Sciences de l'information -- Méthodes statistiques -- Périodiques; Bibliométrie -- Périodiques; 020.727
• DOI: 10.1016/j.joi.2018.12.004
• Languages: English
• ISSNs: 1751-1577

Abstract

Highlights: A backward tracking model for measuring knowledge translation and convergence in the whole translational research spectrum was proposed. Public science plays an important role of public science on pharmaceutical innovation. Basic research is similar with applied research for linking pharmaceutical innovation. It is important for successful pharmaceutical innovation to maintain a balance between scientific and technical knowledge rather than overly reliance on one side. Abstract: We propose a backward tracking model for measuring knowledge transfer in the whole translational research spectrum. Using the drugs-patents-papers-grants backward linkages, we try to figure out the funding-science-technology-innovation translational pattern and ponder some policy implications on e.g., which priority areas and knowledge convergence level are more likely to generate new drugs. The drug-patent linkage data was accessed through the USFDA Orange Book, covering a drug's active ingredient, formulation, or methods of use for approved indications. It will take about 10 years from the application of earliest patent to the approval of the new drug. Also such high-value patents in FDA Orange Book tend to cite scientific knowledge published on average 10–15 years ago. The technology linkage of new drugs was relatively stable while the science linkage of technology inventions increased rapidly. Among the scientific papers cited by drug patents, private-institution originated papers are only a quarter of the public. By linking theses scientific papers with funding sources, we found a large majority (90%) are public-funded and only a very small part are private-funded or public-private joint-funded. Our study also indicates the importance of research on such fields as pharmacology, chemistry (including medicinal chemistry, biochemistry, and organic chemistry), molecular biology, neurosciences, and immunology on new drugs innovation. There is no obvious relationship between "basicness" and linkages to the resulting patents' impact and to drugs innovation. A balanced basic research and applied research maybe essential for fostering drug innovation because it is a complete chain translating from basic discovery to clinical evidence then to clinical practice. In order to achieve successful pharmaceutical innovation, rather than focusing on only technology, convergence with science at moderate levels (maybe 1/3) is suggested.